Protalix BioTherapeutics, Inc. (PLX)

Market Cap	233.22M +35.9%
Revenue (ttm)	61.84M +35.4%
Net Income	5.39M
EPS	0.07
Shares Out	80.42M
PE Ratio	41.99
Forward PE	20.00
Dividend	n/a
Ex-Dividend Date	n/a

Volume	365,161
Open	2.770
Previous Close	2.830
Day's Range	2.770 - 2.920
52-Week Range	1.320 - 3.190
Beta	-0.23
Analysts	Strong Buy
Price Target	12.00 (+313.79%)
Earnings Date	Mar 18, 2026

About PLX

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell e...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 15, 1998
• Employees: 213
• Stock Exchange: NYSEAMERICAN
• Ticker Symbol: PLX
• Website: https://www.protalix.com

Financial Performance

In 2024, Protalix BioTherapeutics's revenue was $53.40 million, a decrease of -18.47% compared to the previous year's $65.49 million. Earnings were $2.93 million, a decrease of -64.73%.

Analyst Summary

According to one analyst, the rating for PLX stock is "Strong Buy" and the 12-month stock price target is $12.0.

Price Target

$12.0

(313.79% upside)

Analyst Consensus: Strong Buy